A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)

Inclusion Criteria:

- Patient has chronic Postherpetic Neuralgia (PHN), defined as pain present for more
than 6 months and less than 10 years after onset of herpes zoster skin rash affecting
a single dermatome. Patients with more than 1 involved dermatome may also be included,
provided the affected dermatomes are contiguous.

- Patient is ≥18 years of age, with a body mass index (BMI) between 18 and 34 kg/m2,
inclusive, at the screening visit.

- If the patient is a woman and is fertile, the patient is not pregnant and has negative
pregnancy tests at both the screening and randomization visits, and agrees to use an
acceptable method of contraception for the duration of the study, including follow-up.

- If the patient is a man and is capable of producing offspring, the patient must agree
to use an acceptable method of contraception, unless the partner cannot become
pregnant for the duration of the study, including follow-up.

- Patient must sign the written Informed Consent Form (ICF) for the study and be willing
to comply with all study procedures and restrictions.

- Patient must be judged by the investigator to be medically healthy (except for PHN)
and able to participate in the study

- Other criteria apply, please contact the investigator for more information

Exclusion Criteria:

- Patient has any other severe pain that might confound assessment or self-evaluation of
pain due to PHN.

- Patient has PHN affecting the face (trigeminal nerve distribution).

- Patient has a history, in the judgment of the investigator, of inadequate response to
more than 3 adequate courses of treatment with other medications used to treat
neuropathic pain (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake
inhibitors, anticonvulsants, topical lidocaine, and/or topical capsaicin).

- Patient is taking oral analgesics (either opioid or non-opioid) or is receiving
topical therapy such as the 5% topical lidocaine patch for the treatment of pain and
is unwilling or unable to complete a washout period during which the patient will
discontinue analgesic therapy or topical pain therapy.

- Patient has been treated with topical capsaicin at any time in the past 6 months for
neuropathic pain.

- Patient has a history of fibromyalgia.

- Other criteria apply, please contact the investigator for more information